Literature DB >> 29018169

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz.   

Abstract

Entities:  

Year:  2017        PMID： 29018169      PMCID： PMC5634779          DOI： 10.1634/theoncologist.2016-0133erratum

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  2 in total

1.  EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.

Authors:  Jingnan An; Yi Du; Xuejun Fan; Yanhong Wang; Cristina Ivan; Xue-Guang Zhang; Anil K Sood; Zhiqiang An; Ningyan Zhang
Journal:  Oncogene       Date:  2018-11-19       Impact factor: 9.867

2.  Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin.

Authors:  B L Burgess; E Cho; L Honigberg
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.